PIM-1 kinase: a potential biomarker of triple-negative breast cancer

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Jieying Chen
Guangyu Tang

Department of Radiology, Shanghai Tenth
People's Hospital, Tongji University
School of Medicine, Shanghai, People's
Republic of China

Abstract: Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (*PIM-1*) gene has been studied for many years. However, its significance in breast cancer remains unclear. In this review we briefly summarized the physiological characteristics and regulation of PIM-1 kinase, and subsequently focused on the role of PIM-1 in tumors, especially breast cancer. Oncogene *PIM-1* was found to be upregulated in breast cancer, especially in triple-negative breast cancer. Moreover, it is involved in tumorigenesis and the development of drug resistance, and linked to poor prognosis. A highly selective probe targeting PIM-1 for imaging has emerged, suggesting that PIM-1 may be a potential biomarker for the accurate diagnosis and targeted therapy of triple-negative breast cancer.

Keywords: triple-negative breast cancer, biomarker, PIM-1

Introduction

Triple-negative breast cancer (TNBC), which is negative for the expression of ER, PR, and HER2, is associated with the poorer prognosis among all types of breast cancer. Since endocrine therapy is ineffective and targeted-therapy is currently unavailable, chemotherapy remains the mainstay of treatment after surgery for TNBC. Therefore, discovering specific biomarkers for the development of early precise diagnosis, effective targeted-therapy, and sensitive assessment of the treatment effect on TNBC is clinically urgent.

The *PIM-1* (*provirus integration site for Moloney murine leukemia virus 1*) gene was identified as an oncogene in mice with leukemia induced by the Moloney murine leukemia virus in the 1980s.¹ PIM-1 kinase, encoded by the *PIM-1* gene, is the most studied and important among all three members of the PIM kinase family. The other two members of the PIM kinase family discovered soon afterwards, PIM-2 and PIM-3, exhibit strong homology to PIM-1. Notably, in-vivo and in-vitro experiments suggested that they can be substitutes of PIM-1 to different extent.²⁻⁴ The human PIM-1 kinase shares >90% similarity at the primary structure level with the mouse PIM-1 protein.^{5,6} PIM-1 kinase was found to be overexpressed in human hematological malignancies,⁷⁻⁹ as well as in numerous human solid tumors such as breast cancer,¹⁰ prostate cancer,¹⁰ gastric cancer,¹¹ and squamous cell carcinoma of the head and neck.¹² The molecular mechanisms of PIM-1-induced tumorigenesis have been studied in great depth. Meanwhile, many different small-molecule inhibitors targeting PIM-1 kinase have been developed. In recent years, increasing

Correspondence: Guangyu Tang
Department of Radiology, Shanghai Tenth
People's Hospital, Tongji University
School of Medicine, 301 Middle Yanchang
Road, Shanghai 200072, People's Republic
of China
Tel +86 1 891 768 3528
Email tgy17@126.com

attention has been paid to the value of PIM-1 in the treatment and diagnosis of tumors. This review aims to explore the potential of PIM-1 kinase as a biomarker of TNBC by briefly summarizing its physiological structure and function, and regulation of the kinase activities of PIM-1. In addition, the association of PIM-1 with tumors and its role in breast cancer are discussed.

Physiological structure and function of PIM-1 kinase

The human *PIM-1* gene is located on chromosome 6p21, and consists of six exons and five introns. It produces a transcript which contains a G/C-rich sequence in the 5' untranslated region (UTR) and five copies of AUUUA destabilizing motifs in the 3' UTR.^{6,13} The use of alternative translation initiation sites (AUG or CUG) results in the synthesis of different protein isoforms: 34 KD and 44 KD PIM-1 kinase (Figure 1).^{14–16} The former isoform is comprised of 313 amino acids, while the latter includes 404 amino acids, both containing the kinase domain.^{17–20}

Both PIM-1 protein isoforms exhibit in vitro serine/threonine kinase activities, and mediate their physiological function by phosphorylating a wide range of cellular substrates,^{19,20} including: 1) cell cycle regulators, such as cyclin-dependent kinase inhibitor 1A/1B (CDKN1A/1B),^{21–24} cell division cycle 25A/C (CDC25A/C),^{25,26} checkpoint kinase 1 (CHK1),²⁷ and forkhead box P3 (FOXP3);²⁸ 2) transcriptional regulators, such as MYC²⁹ and MYB,³⁰ runt-related transcription factor 1/3 (RUNX1/3),³¹ and high mobility group box transcription factor 1 (HBP1);³² 3) signaling intermediates, such as Notch1,¹⁰ suppressor of cytokine signaling 1/3 (SOCS1/3),³³ and mitogen-activated protein kinase kinase 5 (MAP3K5);³⁴ 4) apoptosis signaling kinase 1 (ASK1)³⁴ and apoptosis regulators, such as BCL-2-associated agonist of cell death (BAD);³⁵ 5) protein translation regulators, such as eukaryotic initiation factor 4B (EIF4B);³⁶ and 6) others, such as breast cancer resistant protein (BCRP),²⁴ ubiquitin-like with plant homeo domain and RING finger

domains 1 (UHRF1),³⁷ and androgen receptor (AR) (Table 1).³⁸ Through the phosphorylation of the above substrates, PIM-1 kinase plays a role in cell cycle progression, survival, proliferation, differentiation, apoptosis, and senescence. Xie et al found that 44 KD PIM-1 kinase (located primarily on the plasma membrane), instead of the 34 KD isoform (present in both the cytosol and nucleus), phosphorylated BCRP to protect prostate cancer cells from apoptosis induced by chemotherapeutic drugs.^{39,40} In addition, Katsube et al suggested that 44 KD PIM-1 kinase protected ATP-binding cassette transporter A1 (ABCA1) from lysosomal degradation in hepatocytes, and thereby regulated the circulating level of high-density lipoprotein.⁴¹ However, thus far, almost all research studies investigating human PIM-1 kinase do not consider the two PIM-1 isoforms independently. Further investigation is warranted to determine whether the two isoforms are involved in a single mechanism of regulation of protein expression, or play different biological roles.

Regulation of PIM-1 kinase activities

Structural analysis revealed that the PIM-1 protein contains a constitutively active kinase conformation that does not require to be phosphorylated for activation.¹⁷ This means that the level of PIM-1 enzymatic activity in a cell is dependent on the absolute amount of protein present. Typically, both *PIM-1* mRNA and protein have a relatively short half-life.^{14,39} The regulation of PIM-1 kinase activities largely depends on the induction of transcription and protein degradation, and varies among different cells. Numerous cytokines, growth factors, and mitogens can induce the expression of *PIM-1* in hematological malignancies.^{42–44} In solid tumors, the expression of *PIM-1* may also be induced by hypoxia through hypoxia-inducible factor 1 α (HIF1 α),⁴⁵ DNA damage through Krüppel-like factor 5 (KLF5),⁴⁶ and estrogen through the estrogen receptor.⁴⁷ The majority of these factors transduce their signals through several common signaling pathways, such as the Notch pathway,¹⁰ Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway,^{43,48} and nuclear factor- κ B (NF- κ B) pathway.⁴⁹

Both 5' and 3' UTRs of *PIM-1* mRNA and the alternative translation initiation sites play a vital role in the regulation of *PIM-1* expression.⁵⁰ Eukaryotic translation initiation factor 4E (EIF4E) binds to the m⁷G cap structure in the 5' UTR to regulate the expression of *PIM-1*; this process is termed cap-dependent translation.⁵¹ It was reported that miR328 specifically silenced the expression of *PIM-1* through interaction

Figure 1 *PIM-1* gene and its transcripts and proteins.

Table 1 PIM-1 kinase substrates

Cell cycle regulators	Transcriptional regulators	Signaling intermediates	Apoptosis regulators	Protein translation regulators	Others
CDKN1A CDKN1B CDC25A CDC25C CHK1 FOXP3	MYC MYB RUNX1 RUNX3 HBPI	SOCS1 SOCS3 MAP3K5 Notch1	BAD ASK1	EIF4B	UHRF1 BCRP AR

Abbreviations: PIM-1, provirus integration site for Moloney murine leukemia virus 1; CDKN1A, cyclin-dependent kinase inhibitor 1A, also termed p21 and CIP1; CDKN1B, also termed p27KIP1; CDC25A, cell division cycle 25A, also termed MPIP1; CDC25C, also termed MPIP3; FOXF3, forkhead box P3; RUNX1, runt-related transcription factor 1; HBPI, high mobility group box transcription factor 1; SOCS1, suppressor of cytokine signaling 1; BAD, BCL-2-associated agonist of cell death; ASK1, apoptosis signaling kinase 1; EIF4B, eukaryotic initiation factor 4B; UHRF1, ubiquitin-like with plant homeo domain and RING finger domains 1; BCRP, breast cancer-resistant protein; AR, androgen receptor.

with the *PIM-1* mRNA 3' UTR.⁵² Kim et al found that tristetraprolin bound to the adenylate-uridylylate-rich element 2 in the 3' UTR and enhanced the decay of *PIM-1* mRNA in human prostate cancer.⁵³ Recently, Blanco et al reported that mRNA stability factor HuR (Hu antigen R) interacted with the adenylate-uridylylate-rich elements within the 3' UTR in the context of hypoxia and stabilized the *PIM-1* mRNA, resulting in overexpression of the PIM-1 protein in pancreatic cancer cells.⁵⁴

Ubiquitylation and subsequent proteasomal degradation are the primary post-translational regulation mechanisms of PIM-1 kinase. Research studies showed that heat shock protein 90 β (HSP90 β) can protect PIM-1 kinase from proteasomal degradation and thus, stabilize the protein level.⁵⁵ In contrast, protein phosphatase 2A (PP2A) promotes the ubiquitylation and proteasomal degradation of PIM-1.⁵⁶ PIM-1 kinase has been shown to be constitutively active and does not require prior post-translational modifications for activation. However, Iyer et al⁵⁷ revealed that, in vitro and in cultured cells, PIM-1 was modified by the small ubiquitin-like modifier (SUMO), and SUMOylation promoted the ubiquitin-mediated degradation of PIM-1 via recruitment of the SUMO-targeted ubiquitin ligase RNF4. Additionally, SUMOylated PIM-1 showed enhanced protein kinase activity in vitro. Hence, SUMOylation may govern PIM1 substrate specificity in certain contexts.⁵⁷

PIM-1 kinase and tumors

Following its identification as an oncogene, the relationship between *PIM-1* and tumors has been the emphasis of research. Firstly, upregulation of PIM-1 has been found in prostate cancer,^{10,58,59} squamous cell carcinoma of the head and neck,¹² breast cancer,^{24,35} pancreatic cancer,^{60–62}

gastric cancer,^{11,63} oral squamous cell cancer,⁶⁴ colorectal cancer,⁶⁵ hepatocellular carcinoma,⁶⁶ bladder cancer,⁶⁷ and non-small cell lung cancer,^{68,69} in addition to hematological malignancies. Secondly, dysregulation of PIM-1 has been associated with the invasiveness of cancer cells and patient prognosis. Although earlier studies suggested that upregulation of PIM-1 predicted favorable prognosis in patients with prostate cancer,⁵⁸ pancreatic cancer,⁶¹ and non-small cell lung cancer,⁶⁹ overexpression of PIM-1 has been linked to increasing invasiveness and/or poor prognosis in a large number of cancers (Table 2). Furthermore, the mechanisms of PIM-1-induced tumorigenesis have been studied in great depth. *Ep-Pim-1* transgenic mice overexpressing PIM-1 alone developed lymphoma with long latency and low incidence;⁷⁰ thus *PIM-1* is considered to be a weak oncogene. However, transgenic mice co-expressing PIM-1 and MYC succumbed to lymphomas *in utero* or around birth.⁷¹ Moreover, MYC has been shown to induce tumorigenesis depending on the expression of PIM-1 kinase in lymphoma, prostate cancer, and breast cancer.^{24,70,72,73} In prostate cancer, PIM-1 phosphorylated the serine-62 of c-MYC to induce tumorigenesis,⁷³ while in breast cancer PIM-1 phosphorylated p27 and BAD, in addition to MYC.²⁴ Furthermore, PIM-1 was also reported to phosphorylate AKT, facilitating the glycolysis of hepatocellular carcinoma and promoting tumor growth and metastasis.⁶⁶ These findings suggest that PIM-1 may be involved in the development, progression, and maintenance of tumors via different mechanisms. This is consistent with the varied regulation of *PIM-1* expression within different types of cells mentioned above. Of note, PIM-1 induced tumorigenesis in a variety of tumors, *PIM-1* knockouts exerted only subtle effects without influence on growth and reproduction,⁷⁴ and mice deficient for all members of the *PIM* family (*PIM-1*, 2, 3) are

Table 2 PIM-1 and prognosis of tumors

Tumors	Dysregulation	Prognosis
Lymphoma ⁷⁻⁹	Up	Correlated to poor prognosis
Prostate cancer ⁵⁸	Up	Correlated to favorable prognosis
Prostate cancer ⁵⁹	Up	Related to the grade and neoplastic transformation
Pancreatic cancer ^{60,62}	Up	Correlated to poor prognosis
Pancreatic cancer ⁶¹	Up	Has a positive prognostic impact
Non-small cell lung cancer ⁶⁸	Up	Associated with an increase in pathological grade, lymph node metastasis, and advanced clinical stage
Non-small cell lung cancer ⁶⁹	Down	Associated with the occurrence of lymph node metastases
Gastric cancer ^{11,63}	Up	Inversely correlated to the presence of lymphovascular invasion
Squamous cell carcinoma of head and neck ¹²	Up	Correlated to poor response to radiation therapy
Oral squamous cell cancer ⁶⁴	Up	NR
Breast cancer ^{24,35}	Up	Associated with a significantly higher risk of recurrence
Colorectal cancer ⁶²	Up	NR
Hepatocellular carcinoma ⁶⁵	Up	Promoted tumor growth and metastasis
Bladder cancer ⁶⁷	Up	Plays a role in the initiation and progression of bladder cancer

Abbreviation: NR, not reported.

viable and fertile, displaying only reduced body size and impaired responses to hematopoietic growth factors.⁷⁵ Based on this evidence, several research groups have generated structurally different small-molecule inhibitors targeting PIM kinases, with currently ongoing preclinical and clinical trials testing their potency for tumor inhibition.⁴²

Roles of PIM-1 kinase in breast cancer

Although research on the expression and function of PIM-1 kinase in breast cancer has not been as extensive as that for other solid tumors (eg, prostate cancer), great progress in determining its roles in this type of cancer has been achieved in recent years. In 2006, Gapter et al demonstrated that the levels of both PIM-1 mRNA and protein were upregulated in breast cancer cells compared with those reported in normal breast epithelial cells.²¹ A subsequent study also reported that the expression of *PIM-1* mRNA in human breast cancer was higher than that observed in benign breast tumors. Moreover, elevated *PIM-1* expression was associated with malignancy and a higher tumor grade.⁴⁷ Recently, a study performed by Jimenez-Garcia et al and based on several public databases revealed that the expression of PIM-1 was significantly increased in breast cancer compared with normal breast epithelium. Patients with higher *PIM-1* expression were associated with worse prognosis in relapsed and treatment-resistant tumors.⁷⁶ This evidence indicates that upregulation of PIM-1 may be a biomarker of breast cancer.

In 2016, Braso-Maristany et al³⁵ noticed that oncogene *PIM-1* is located on a genomic recurrent amplification region of 6p21-p25 in TNBC. They investigated whether the copy-number status and expression levels of *PIM-1* are increased in TNBC by analyzing three independent published datasets. The results showed that the levels of *PIM-1* mRNA were significantly higher in TNBC compared with those measured in non-TNBC. Furthermore, *PIM-1* gene expression was significantly correlated with its copy number in TNBC.³⁵ Meanwhile, Horiuchi et al²⁴ identified nine kinases that were selectively required for the survival of MYC-activated non-immortalized human mammary epithelial cells, among which PIM-1 exhibited the greatest efficacy in maintaining survival. Analysis of four distinct clinical cohorts revealed that *PIM-1* mRNA expression was significantly elevated in TNBC compared with that reported in non-TNBC. In addition, increased *PIM-1* expression was associated with poor prognosis in patients with hormone receptor-negative tumors.²⁴ These findings, related to the functions of *PIM-1* in TNBC, indicated that *PIM-1* mediated survival, tumor growth, and response to chemotherapy in cooperation with MYC in TNBC. Moreover, small-molecule inhibitors of PIM kinase halted the growth of human TNBC in a mouse model and sensitized TNBC to standard-of-care chemotherapy.^{24,35}

Recently, Guo et al generated a highly selective red-emitting fluorescent probe targeting PIM-1 kinase for imaging cancer cells.⁷⁷ This probe successfully distinguished breast cancer cells overexpressing PIM-1 kinase from

normal cells in vitro and in vivo. In summary, the aforementioned findings demonstrate that upregulation of PIM-1 may be an important molecular event during the development and progression of TNBC. Thus, PIM-1 may be a reliable biomarker for the diagnosis, treatment, and prognosis of TNBC.

Conclusion and perspectives

After nearly 40 years of research, we have developed a deep understanding of the physiological structure and function of PIM-1. The role of PIM-1 in tumorigenesis has been determined to a certain extent. Exciting results have been obtained from studies involving treatment targeted to PIM-1 in lymphoma⁷⁸ and prostate cancer.⁷⁹ PIM-1 is overexpressed in TNBC and associated with cell survival, tumor growth, and resistance to chemotherapy in this setting.^{24,35} Therefore, PIM-1 may be a reliable biomarker of TNBC. Further studies are warranted to investigate the relationship between PIM-1 and MYC in TNBC, and develop highly selective compounds against PIM-1. Such investigations will provide a new opportunity for the diagnosis and treatment of TNBC.

Acknowledgment

This study was funded by the National Natural Science Foundation of China (No 81871325, 81801656).

Disclosure

The authors report no conflict of interest in this work.

References

- Cuyper HT, Selten G, Quint W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. *Cell*. 1984;37(1):141. doi:10.1016/0092-8674(84)90309-X
- Mikkers H, Allen J, Knipscheer P, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. *Nat Genet*. 2002;32(1):153–159. doi:10.1038/ng950
- Feldman JD, Vician L, Crispino M, et al. KID-1, a protein kinase induced by depolarization in brain. *J Biol Chem*. 1998;273(26):16535–16543. doi:10.1074/jbc.273.26.16535
- Baytel D, Shalom S, Madgar I, Weissenberg R, Don J. The human Pim-2 proto-oncogene and its testicular expression. *Biochim Biophys Acta*. 1998;1442(2–3):274–285.
- Domen J, Von Lindern M, Hermans A, Breuer M, Grosveld G, Berns A. Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence and immunological identification of the in vitro synthesized PIM-1 protein. *Oncogene Res*. 1987;1(1):103–112.
- Zakut-Houri R, Hazum S, Givol D, Telerman A. The cDNA sequence and gene analysis of the human pim oncogene. *Gene*. 1987;54(1):105–111. doi:10.1016/0378-1119(87)90352-0
- Bellon M, Lu L, Nicot C. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. *Blood*. 2016;127(20):2439–2450. doi:10.1182/blood-2015-11-685032
- Lilly M, Le T, Holland P, Hendrickson SL. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. *Oncogene*. 1992;7(4):727.
- Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med*. 2006;354(23):2431–2442. doi:10.1056/NEJMoa055759
- Santio NM, Landor SK, Vahtera L, et al. Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells. *Oncotarget*. 2016;7(28):43220–43238. doi:10.18632/oncotarget.9215
- Warnecke-Eberz U, Bollschweiler E, Drebber U, et al. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. *Anticancer Res*. 2009;29(11):4451–4455.
- Peltola K, Hollmen M, Maula SM, et al. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. *Neoplasia*. 2009;11(7):629–636. doi:10.1593/neo.81038
- Meeker TC, Nagarajan L, ar-Rushdi A, Rovera G, Huebner K, Croce CM. Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family. *Oncogene Res*. 1987;1(1):87–101.
- Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. *EMBO J*. 1991;10(3):655–664.
- Padma R, Nagarajan L. The human PIM-1 gene product is a protein serine kinase. *Cancer Res*. 1991;51(9):2486–2489.
- Telerman A, Amson R, Zakut-Houri R, Givol D. Identification of the human pim-1 gene product as a 33-kilodalton cytoplasmic protein with tyrosine kinase activity. *Mol Cell Biol*. 1988;8(4):1498–1503. doi:10.1128/mcb.8.4.1498
- Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. *J Biol Chem*. 2005;280(7):6130–6137. doi:10.1074/jbc.M409123200
- Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. *J Mol Biol*. 2005;348(1):183–193. doi:10.1016/j.jmb.2005.02.039
- Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. Structure and substrate specificity of the Pim-1 kinase. *J Biol Chem*. 2005;280(50):41675–41682. doi:10.1074/jbc.M510711200
- Bachmann M, Moroy T. The serine/threonine kinase Pim-1. *Int J Biochem Cell Biol*. 2005;37(4):726–730. doi:10.1016/j.biocel.2004.11.005
- Gapter LA, Magnuson NS, Ng KY, Hosick HL. Pim-1 kinase expression during murine mammary development. *Biochem Biophys Res Commun*. 2006;345(3):989–997. doi:10.1016/j.bbrc.2006.04.110
- Wang Z, Bhattacharya N, Mixer PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. *Biochim Biophys Acta*. 2002;1593(1):45–55. doi:10.1016/s0167-4889(02)00347-6
- Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. *Cancer Res*. 2008;68(13):5076–5085. doi:10.1158/0008-5472.CAN-08-0634
- Horiuchi D, Camarda R, Zhou AY, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. *Nat Med*. 2016;22(11):1321–1329. doi:10.1038/nm.4213
- Bachmann M, Kosan C, Xing PX, Montemari M, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. *Int J Biochem Cell Biol*. 2006;38(3):430–443. doi:10.1016/j.biocel.2005.10.010
- Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. *J Biol Chem*. 1999;274(26):18659–18666. doi:10.1074/jbc.274.26.18659

27. Yuan LL, Green AS, Bertoli S, et al. Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia. *Leukemia*. 2014;28(2):293–301. doi:10.1038/leu.2013.168
28. Li Z, Lin F, Zhuo C, et al. PIM1 kinase phosphorylates the human transcription factor FOXp3 at serine 422 to negatively regulate its activity under inflammation. *J Biol Chem*. 2014;289(39):26872–26881. doi:10.1074/jbc.M114.586651
29. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. *Oncogene*. 2008;27(35):4809–4819. doi:10.1038/onc.2008.123
30. Winn LM, Lei W, Ness SA. Pim-1 phosphorylates the DNA binding domain of c-Myb. *Cell Cycle*. 2003;2(3):258–262.
31. Aho TL, Sandholm J, Peltola KJ, Ito Y, Koskinen PJ. Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity. *BMC Cell Biol*. 2006;7:21. doi:10.1186/1471-2121-7-21
32. Wang S, Cao Z, Xue J, et al. A positive feedback loop between Pim-1 kinase and HBP1 transcription factor contributes to hydrogen peroxide-induced premature senescence and apoptosis. *J Biol Chem*. 2017;292(20):8207–8222. doi:10.1074/jbc.M116.768101
33. Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. *Blood*. 2004;103(10):3744–3750. doi:10.1182/blood-2003-09-3126
34. Gu JJ, Wang Z, Reeves R, Magnuson NS. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. *Oncogene*. 2009;28(48):4261–4271. doi:10.1038/onc.2009.276
35. Braso-Maristany F, Filosto S, Catchpole S, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. *Nat Med*. 2016;22(11):1303–1313. doi:10.1038/nm.4198
36. Yang J, Wang J, Chen K, et al. eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. *Cancer Res*. 2013;73(15):4898–4908. doi:10.1158/0008-5472.CAN-12-4277
37. Yang J, Liu K, Yang J, et al. PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311. *Oncogene*. 2017;36(34):4828–4842. doi:10.1038/onc.2017.96
38. Ha S, Iqbal NJ, Mita P, et al. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. *Oncogene*. 2013;32(34):3992–4000. doi:10.1038/onc.2012.412
39. Xie Y, Xu K, Dai B, et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. *Oncogene*. 2006;25(1):70–78. doi:10.1038/sj.onc.1209058
40. Xie Y, Xu K, Linn DE, et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. *J Biol Chem*. 2008;283(6):3349–3356. doi:10.1074/jbc.M707773200
41. Katsube A, Hayashi H, Kusuhashi H. Pim-1L protects cell surface-resident ABCA1 from lysosomal degradation in hepatocytes and thereby regulates plasma high-density lipoprotein level. *Arterioscler Thromb Vasc Biol*. 2016;36(12):2304–2314. doi:10.1161/ATVBAHA.116.308472
42. Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. *Biochem Pharmacol*. 2013;85(5):629–643. doi:10.1016/j.bcp.2012.09.018
43. Matikainen S, Sarenava T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. *Blood*. 1999;93(6):1980–1991.
44. Wang Z, Bhattacharya N, Weaver M, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. *J Vet Sci*. 2001;2(3):167–179.
45. Casillas AL, Toth RK, Sainz AG, et al. Hypoxia-inducible PIM kinase expression promotes resistance to antiangiogenic agents. *Clin Cancer Res*. 2018;24(1):169–180. doi:10.1158/1078-0432.CCR-17-1318
46. Zhao Y, Hamza MS, Leong HS, et al. Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells. *Oncogene*. 2008;27(1):1–8. doi:10.1038/sj.onc.1210625
47. Malinen M, Jaaskelainen T, Pelkonen M, et al. Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. *Mol Cell Endocrinol*. 2013;365(2):270–276. doi:10.1016/j.mce.2012.10.028
48. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. *Immunity*. 1999;11(6):709–719.
49. Zhang Y, Parsanejad M, Huang E, et al. Pim-1 kinase as activator of the cell cycle pathway in neuronal death induced by DNA damage. *J Neurochem*. 2010;112(2):497–510. doi:10.1111/j.1471-4159.2009.06476.x
50. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. *Nat Rev Cancer*. 2011;11(1):23–34. doi:10.1038/nrc2986
51. Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor eIF-4E. *Cell Growth Differ*. 1997;8(12):1371–1380.
52. Eiring AM, Harb JG, Neviani P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. *Cell*. 2010;140(5):652–665. doi:10.1016/j.cell.2010.01.007
53. Kim HK, Kim CW, Vo MT, et al. Expression of proviral integration site for Moloney murine leukemia virus 1 (Pim-1) is post-transcriptionally regulated by tristetraprolin in cancer cells. *J Biol Chem*. 2012;287(34):28770–28778. doi:10.1074/jbc.M112.376483
54. Blanco FF, Jimbo M, Wulfschuh J, et al. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. *Oncogene*. 2016;35(19):2529–2541. doi:10.1038/onc.2015.325
55. Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, Hirano T. Regulation of Pim-1 by Hsp90. *Biochem Biophys Res Commun*. 2001;281(3):663–669. doi:10.1006/bbrc.2001.4405
56. Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. *Oncogene*. 2007;26(35):5145. doi:10.1038/sj.onc.1210323
57. Iyer RS, Chatham L, Sleight R, Meek DW. A functional SUMO-motif in the active site of PIM1 promotes its degradation via RNF4, and stimulates protein kinase activity. *Sci Rep*. 2017;7(1):3598. doi:10.1038/s41598-017-03775-w
58. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. *Nature*. 2001;412(6849):822–826. doi:10.1038/35090585
59. Xu Y, Zhang T, Tang H, et al. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. *J Surg Oncol*. 2005;92(4):326–330. doi:10.1002/jso.20325
60. Xu J, Zhang T, Wang T, You L, Zhao Y. PIM kinases: an overview in tumors and recent advances in pancreatic cancer. *Future Oncol*. 2014;10(5):865–876. doi:10.2217/fon.13.229
61. Reiser-Erkan C, Erkan M, Pan Z, et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. *Cancer Biol Ther*. 2008;7(9):1352–1359. doi:10.4161/cbt.7.9.6418
62. Xu J, Xiong G, Cao Z, et al. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. *J Exp Clin Cancer Res*. 2016;35(1):133. doi:10.1186/s13046-016-0406-z
63. Yan B, Yau EX, Samanta S, et al. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. *Gastric Cancer*. 2012;15(2):188–197. doi:10.1007/s10120-011-0097-2
64. Chiang WF, Yen CY, Lin CN, et al. Up-regulation of a serine-threonine kinase proto-oncogene Pim-1 in oral squamous cell carcinoma. *Int J Oral Maxillofac Surg*. 2006;35(8):740–745. doi:10.1016/j.ijom.2006.01.027

65. Peng YH, Li JJ, Xie FW, et al. Expression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients. *PLoS One*. 2013;8(10):e76693. doi:10.1371/journal.pone.0076693
66. Leung CO, Wong CC, Fan DN, et al. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. *Oncotarget*. 2015;6(13):10880–10892. doi:10.18632/oncotarget.3534
67. Guo S, Mao X, Chen J, et al. Overexpression of Pim-1 in bladder cancer. *J Exp Clin Cancer Res*. 2010;29:161. doi:10.1186/1756-9966-29-161
68. Jin Y, Tong DY, Chen JN, et al. Overexpression of osteopontin, alphavbeta3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. *PLoS One*. 2012;7(10):e48575. doi:10.1371/journal.pone.0048575
69. Warnecke-Eberz U, Bollschweiler E, Drebbler U, et al. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases. *Oncol Rep*. 2008;20(3):619–624.
70. van Lohuizen M, Verbeek S, Krimpenfort P, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. *Cell*. 1989;56(4):673–682. doi:10.1016/0092-8674(89)90589-8
71. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. *Mol Cell Biol*. 1991;11(2):1176–1179. doi:10.1128/mcb.11.2.1176
72. Wang J, Anderson PD, Luo W, Gius D, Roh M, Abdulkadir SA. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. *Oncogene*. 2012;31(14):1794–1803. doi:10.1038/onc.2011.371
73. Wang J, Kim J, Roh M, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. *Oncogene*. 2010;29(17):2477–2487. doi:10.1038/onc.2010.10
74. Laird PW, van der Lugt NM, Clarke A, et al. In vivo analysis of Pim-1 deficiency. *Nucleic Acids Res*. 1993;21(20):4750–4755. doi:10.1093/nar/21.20.4750
75. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. *Mol Cell Biol*. 2004;24(13):6104–6115. doi:10.1128/MCB.24.13.6104-6115.2004
76. Jimenez-Garcia MP, Lucena-Cacace A, Robles-Frias MJ, et al. Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. *Oncotarget*. 2017;8(35):58872–58886. doi:10.18632/oncotarget.19438
77. Guo S, Fan J, Wang B, et al. Highly selective red-emitting fluorescent probe for imaging cancer cells in situ by targeting Pim-1 kinase. *ACS Appl Mater Interfaces*. 2018;10(2):1499–1507. doi:10.1021/acsami.7b14553
78. Cortes J, Tamura K, DeAngelo DJ, et al. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. *Br J Cancer*. 2018;118(11):1425–1433. doi:10.1038/s41416-018-0082-1
79. Mologni L, Magistroni V, Casuscelli F, Montemartini M, Gambacorti-Passerini C. The novel PIM1 inhibitor NMS-P645 reverses PIM1-dependent effects on TMPRSS2/ERG positive prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition. *J Cancer*. 2017;8(1):140–145. doi:10.7150/jca.15838

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

Dovepress